UBS Group’s Quest Diagnostics DGX Stock Holding History

UBS Group’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-42,822	Closed	-$5.1M	–	9074
2020 Q4	$5.1M	Buy	+42,822	New	+$5.22M	﹤0.01%	2426
2020 Q1	–	Sell	-20,800	Closed	-$2.22M	–	8025
2019 Q4	$2.22M	Buy	+20,800	New	+$2.17M	﹤0.01%	3448
2018 Q3	–	Sell	-15,400	Closed	-$1.69M	–	8023
2018 Q2	$1.69M	Buy	+15,400	New	+$1.6M	﹤0.01%	3315
2018 Q1	–	Sell	-86,400	Closed	-$8.51M	–	7875
2017 Q4	$8.51M	Buy	86,400 +76,400	+764%	+$7.24M	﹤0.01%	1865
2017 Q3	$936K	Buy	+10,000	New	+$1.06M	﹤0.01%	3768
2015 Q1	–	Sell	-41,000	Closed	-$2.75M	–	8915
2014 Q4	$2.75M	Buy	+41,000	New	+$2.59M	﹤0.01%	2602

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

UBS Group's DGX Position: Q2 2026 in Review

UBS Group increased its Quest Diagnostics (DGX) stake by 27% in Q2 2026, buying an estimated $36.6M and bringing the position to 888,906 shares worth $188M. The position accounts for 0.02% of the portfolio, ranked #701.

UBS Group first reported a position in DGX in Q4 2014 and has held it in 47 quarters since. The position peaked at $193M in Q4 2025. 1,109 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

UBS Group held 888,906 shares of Quest Diagnostics worth $188M as of Q2 2026.
UBS Group bought 186,569 Quest Diagnostics shares in Q2 2026, an estimated $36.6M.
Quest Diagnostics made up 0.02% of UBS Group's portfolio in Q2 2026, its #701 holding.
UBS Group first reported a position in Quest Diagnostics in Q4 2014 and has held it in 47 quarters since.
UBS Group's Quest Diagnostics position peaked at $193M in Q4 2025.
1,109 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.